Quantcast

Latest Geron Corporation Stories

2014-09-23 08:29:34

President-Elect of the Society for Cryobiology and Former Cell Therapy Executive Join Leading Clinicians, Developers, and Consultants in the Biobanking, Drug Discovery, and Regenerative Medicine Markets BOTHELL, Wash., Sept. 23, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or...

2014-09-11 08:27:28

-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in...

2014-09-04 16:27:31

MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date") for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution. Asterias plans to distribute, on a pro rata basis, warrants to purchase 8,000,000 BioTime common...

2014-08-27 08:26:50

Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the...

2014-08-21 08:28:11

- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three...

2014-07-24 16:26:46

- Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., July 24, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To...

2014-05-29 08:30:21

SAN DIEGO, May 29, 2014 /PRNewswire/ -- ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes, announced today that the Company has settled a patent dispute involving certain of the Company's definitive endoderm patents and patent applications. The dispute involved an appeal to the U.S. District Court by Asterias Biotherapeutics, Inc., (as assignee of Geron Corporation), which...

2014-04-14 23:02:50

Transparency Market Research Report added "Human Embryonic Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse full report:- http://www.transparencymarketresearch.com/human-embryonic-stem-cells.html. Albany, NY (PRWEB) April 14, 2014 Human embryonic stem cells (hESCs) are derived from blastocyst and are capable of differentiating into number of cell types that make up the human body. hESCs can replicate...

2014-04-07 08:29:33

NEW YORK, April 7, 2014 /PRNewswire/ -- Geron Corporation (NasdaqGS: GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies. Through internal efforts and potential future strategic partnerships, GERN is positioned to advance the commercialization of Imetelstat in one or more hematologic myeloid malignancies. The discovery and early development of Imetelstat was based on Geron's core expertise in telomerase and...

2014-04-01 20:21:51

DUBLIN, April 2, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7vkq8r/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast to 2020" [http://www.researchandmarkets.com/research/7vkq8r/global_stem_cell ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related